Teunissen Charlotte E, Verberk Inge M W, Thijssen Elisabeth H, Vermunt Lisa, Hansson Oskar, Zetterberg Henrik, van der Flier Wiesje M, Mielke Michelle M, Del Campo Marta
Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.
多年来，用于阿尔茨海默病的血液生物标志物似乎遥不可及，但最近的研究结果表明它们有望成为现实。采用新型高灵敏度检测方法所产生的令人信服的数据在不同队列中呈现出显著的一致性，而且与所使用的具体分析方法无关。血液中淀粉样蛋白和磷酸化tau蛋白的浓度与脑脊液中的相应浓度以及淀粉样蛋白PET或tau蛋白PET扫描结果相关。此外，其他基于血液的神经退行性变生物标志物，如神经丝轻链和胶质纤维酸性蛋白，似乎能够提供有关疾病进展以及监测治疗效果潜力的信息。现在问题来了，我们何时以及如何将这些生物标志物应用于临床实践。这一步将为基于血液的生物标志物支持阿尔茨海默病和其他痴呆症的诊断及治疗发展铺平道路。
